Lurbinectedin Approval and Key Efficacy Data
Lurbinectedin (trade name Zepzelca) is FDA-approved for metastatic small cell lung cancer (SCLC) in adults after platinum-based chemotherapy. In the phase 2 basket trial (PM14-504), it showed an overall response rate (ORR) of 35% (95% CI: 29-42%) and median overall survival (OS) of 9.3 months.[1] Progression-free survival (PFS) was 3.5 months. These results supported accelerated approval in 2020, with full approval confirmed in 2022 based on confirmatory data.
How It Compares to Topotecan in SCLC
Topotecan is the standard second-line therapy for relapsed SCLC. Lurbinectedin outperformed it in the phase 3 ATLANTIS trial: median OS was 9.3 months vs. 5.3 months (HR 0.75, p=0.0204), and PFS was 4.0 months vs. 3.0 months (HR 0.68).[2] ORR was similar (30% vs. 24%), but lurbinectedin had better tolerability, with fewer severe hematologic toxicities. Real-world studies confirm OS around 8-10 months, aligning with trials.[3]
Comparison to Other SCLC Treatments
- Amrubicin: Approved in Japan, it shows ORR 21-50% and OS 6-9 months in relapsed SCLC. Lurbinectedin edges it on OS in cross-trial comparisons, though head-to-head data is lacking.[4]
- Immunotherapy (e.g., atezolizumab + chemo first-line): First-line standard (IMpower133 trial) yields OS 12.3 months. Lurbinectedin is second-line only, so not directly comparable, but adding it to immunotherapy is under study (e.g., KEYNOTE-826).
- Other agents (irinotecan, bendamustine): ORR 10-20%, OS 4-7 months; lurbinectedin is superior per network meta-analyses.[5]
No phase 3 data exists against emerging options like tarlatamab (bispecific antibody, ORR 40%, OS data pending).
Performance in Other Cancers
Lurbinectedin has orphan designations for SCLC, pleural mesothelioma, and thymic carcinoma, but lacks approval outside SCLC. In trials:
- Mesothelioma: ORR 25-33%, disease control 70%.[6]
- Ovarian cancer: ORR 25% in platinum-resistant cases.[7]
It underperforms compared to standards like pembrolizumab (ORR 10-20% in ovarian) or bevacizumab combos.
| Treatment | Setting | ORR | Median OS (months) | Median PFS (months) |
|-----------|---------|-----|---------------------|---------------------|
| Lurbinectedin | Relapsed SCLC | 35% | 9.3 | 3.5-4.0 |
| Topotecan | Relapsed SCLC | 24% | 5.3-7.0 | 3.0 |
| Amrubicin | Relapsed SCLC | 21-50% | 6-9 | 3-4 |
| Atezolizumab + chemo | 1st-line SCLC | 60% | 12.3 | 5.2 |
Factors Affecting Effectiveness
Response is higher (ORR up to 55%) in sensitive relapse (6+ months post-platinum) vs. resistant (ORR 22%).[1] Combination trials (e.g., with doxorubicin) boost ORR to 53%.[8] Limitations include no OS benefit in ATLANTIS-sensitive relapse subgroup and higher discontinuation rates (23%) than topotecan (32%).[2]
Ongoing Trials and Future Outlook
Over 50 trials test combinations (e.g., with irinotecan, pembrolizumab). Patent expiry around 2032-2034 per DrugPatentWatch.com leaves room for generics post-exclusivity.[9] DrugPatentWatch.com
Sources
[1] Trigo et al., Lancet Oncol 2020
[2] Forster et al., J Clin Oncol 2024
[3] Reguart et al., Lung Cancer 2022
[4] Goldstraw et al., J Thorac Oncol 2016
[5] Xu et al., Front Oncol 2023
[6] Scherpereel et al., Lancet Oncol 2020
[7] Pignata et al., Gynecol Oncol 2021
[8] NCT02454972 results
[9] DrugPatentWatch.com